Zobrazeno 1 - 10
of 25
pro vyhledávání: '"N V Dobrova"'
Publikováno v:
Современная онкология, Vol 14, Iss 4, Pp 32-35 (2012)
Externí odkaz:
https://doaj.org/article/e69118c460b347d088878dba3fa890ed
Autor:
M R Lichinitser, N V Dobrova, A M Garin, I S Bazin, V A Gorbunova, E K Voznyy, N Yu Dobrovol'skaya, I B Kononenko, S V Odintsov
Publikováno v:
Современная онкология, Vol 3, Iss 1, Pp 32-33 (2001)
Колоректальный рак занимает одно из основных мест в структуре онкологических заболеваний человека, особенно в экономически развитых с
Externí odkaz:
https://doaj.org/article/0f67b2e1363b427cace7d176b9016a76
Autor:
N. V. Dobrova, A. D. Darenskaya
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 92-102 (2019)
Introduction. Colorectal cancer (CRC) holds leading positions in the cancer incidence and mortality patterns worldwide. In this regard, the study of new effective drugs and development of new treatment regimens for advanced CRC is receiving priority
Externí odkaz:
https://doaj.org/article/584ffa4ba4aa48e7b6d6954d81a8b0e5
Publikováno v:
Тазовая хирургия и онкология, Vol 9, Iss 1, Pp 51-59 (2019)
Objective: to evaluate the prognostic value of Bax expression in the primary colon tumor of patients with metastatic colorectal cancer (mCRC) receiving first-line treatment with a triple combination of irinotecan + oxaliplatin + long-term infusion of
Externí odkaz:
https://doaj.org/article/70f87897220c45e2a20a3bf950611303
Publikováno v:
Тазовая хирургия и онкология, Vol 9, Iss 1, Pp 19-25 (2019)
This review analyzes clinical significance of Bax biomarker in colorectal cancer. We cover the most important characteristics of this protein, describe its role in the apoptosis regulation mechanisms, and asses its prognostic value. Despite the fact
Externí odkaz:
https://doaj.org/article/87be379ab5564c4a9ddba42cb903fe8e
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 32-41 (2018)
Today, the researchers continue the search for the most optimal regimens of drug therapy for metastatic colorectal cancer (mCRC) which are supposed to increase progression-free survival (PFS) and overall survival (OS), improve patient quality of life
Externí odkaz:
https://doaj.org/article/5c1e7ec8e875471081f50abb4e1881bf
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 56-60 (2018)
The article considers the place of nab-paclitaxel in the treatment of metastatic breast cancer. A number of studies have shown high efficacy and acceptable toxicity in comparison with traditional taxanes. The low frequency of hypersensitivity reactio
Externí odkaz:
https://doaj.org/article/828fe9378db24020b033974b516a9be6
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 42-49 (2018)
A study that enrolled 30 patients with advanced colorectal cancer, who had not previously received any specific drug treatment, was conducted to develop and study a three-component regimen with oral fluoropyrimidine tegafur (Ftorafur) in outpatient p
Externí odkaz:
https://doaj.org/article/8c8f06961c0947918a488b8c520ae5a4
Publikováno v:
Тазовая хирургия и онкология, Vol 8, Iss 3, Pp 26-35 (2018)
Background. The evaluation of clinical and morphological characteristics is not sufficient to predict the prognosis of metastatic colorectal cancer (mRCC). Tumor aggressiveness may vary significantly even in patients with similar clinical and morphol
Externí odkaz:
https://doaj.org/article/57a9f37673264f2887f8913b1cc9f481
Autor:
A. D. Darenskaya, N. V. Dobrova
Publikováno v:
Тазовая хирургия и онкология, Vol 8, Iss 1, Pp 50-66 (2018)
Background. Despite the fact that treatment of metastatic colorectal cancer (mCRC) has undergone major advances in recent decades, long-term results remain unsatisfactory. Therefore, the development of new first-line therapeutic regimens for mCRC is
Externí odkaz:
https://doaj.org/article/1864a99e3f6b43fc8e971d2ada0543c9